<DOC>
	<DOCNO>NCT00381862</DOCNO>
	<brief_summary>RATIONALE : Aprepitant , palonosetron , dexamethasone may help lessen prevent nausea vomit patient receive chemotherapy . PURPOSE : This phase II trial study well give aprepitant together palonosetron dexamethasone work prevent nausea vomit cause chemotherapy patient receive chemotherapy metastatic colorectal cancer .</brief_summary>
	<brief_title>Phase II Trial Evaluating Efficacy Tolerability Aprepitant &amp; Palonosetron Prevention Chemotherapy-Induced Nausea Vomiting</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate efficacy , term nausea vomit control , aprepitant , palonosetron hydrochloride , dexamethasone , prevent chemotherapy-induced nausea vomit patient receive FOLFOX FOLFIRI chemotherapy metastatic colorectal cancer . Secondary - Assess percentage patient emesis rescue therapy treat aprepitant , palonosetron hydrochloride , dexamethasone repeat course FOLFOX FOLFIRI chemotherapy . - Assess effect aprepitant nausea , appetite , taste change ( via visual analogue scale ) , nutritional intake , mucositis patient . - Assess safety regimen patient . OUTLINE : This open-label , multicenter study . Beginning 1 hour prior initiation chemotherapy day 1 , patient receive oral aprepitant day 1-3 , oral dexamethasone day 1-4 , palonosetron hydrochloride IV day 1 . Nausea assess daily 4 course chemotherapy . Quality life assess baseline . PROJECTED ACCRUAL : A total 100 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis colorectal cancer Metastatic disease Scheduled receive 1 follow chemotherapy regimens* : FOLFOX 4 ( oxaliplatin , fluorouracil , leucovorin calcium ) FOLFOX 6 FOLFOX 7 FOLFIRI ( irinotecan hydrochloride , fluorouracil , leucovorin calcium ) NOTE : *Regimens may also include cetuximab bevacizumab No emesis requirement antiemetic agent within 48 hour prior begin chemotherapy Singleagent benzodiazepine hypnotic allow No chronic nausea PATIENT CHARACTERISTICS : Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Life expectancy &gt; 4 month White Blood Cell ( WBC ) count &gt; 3,000/mm^³ Absolute neutrophil count ( ANC ) &gt; 1,500/mm^³ Platelet count &gt; 100,000/mm^³ Bilirubin ≤ 2.5 time upper limit normal ( ULN ) ( &lt; 5 time ULN liver metastasis present ) Creatinine ≤ 1.5 time ULN Aspartate aminotransferase ( AST ) Alanine aminotransferase ( ALT ) ≤ 2.5 time ULN ( &lt; 5 time ULN liver metastasis present ) Able swallow tablet capsule No known sensitivity aprepitant , palonosetron hydrochloride , dexamethasone Not pregnant nursing Negative pregnancy test No history consume ≥ 5 alcoholic drinks/day within past year No concurrent illness require systemic corticosteroid plan dexamethasone study treatment No clinical sign active systemic infection involve gastrointestinal tract No active bowel obstruction PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior chemotherapy &gt; Hesketh level 3 Prior fluorouracil without leucovorin calcium capecitabine allow At least 30 day since prior investigational drug At least 14 day since prior neurokinin1 antagonist Concurrent hydrocortisone physiologic replacement dos ( ≤ 30 mg/day ) allow No concurrent chronic antiemetic agent Concurrent hypnotic allow Concurrent rescue antiemetic allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>nausea vomit</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
</DOC>